SKI Market

A+| A| A-| Skip to Main Content

Indian Indices

Sensex

74,459.53 308.49
( 0.42%)

Global Indices

Nasdaq

51,732.40 -631.16
(-1.21%)

Dow Jones

7,581.68 -159.71
(-2.06%)

Hang Seng

63,176.05 -1,483.42
(-2.29%)

Nikkei 225

10,722.51 0.44
(0.00%)

Forex

USD-INR

95.22 0.06
(0.06%)

EUR-INR

106.19 0.24
(0.23%)

GBP-INR

127.01 0.44
(0.35%)

JPY-INR

0.60 0.00
(0.12%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Valiant Laboratories Ltd

Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln

BSE Code

ISIN Demat

Book Value()

543998

INE0JWS01017

58.8738688

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

VALIANTLAB

52.63

694.66

EPS(TTM)

Face Value()

Div & Yield %

2.43

Back

Elantas Beck India standalone net profit declines 5.45% in the March 2026 quarter

May 13,2026

Net profit of Elantas Beck India declined 5.45% to Rs 31.08 crore in the quarter ended March 2026 as against Rs 32.87 crore during the previous quarter ended March 2025. Sales rose 7.78% to Rs 222.17 crore in the quarter ended March 2026 as against Rs 206.13 crore during the previous quarter ended March 2025.

Particulars	Quarter Ended
	Mar. 2026	Mar. 2025	% Var.
Sales	222.17	206.13	8
OPM %	19.52	19.59	-
PBDT	46.15	48.95	-6
PBT	40.42	44.29	-9
NP	31.08	32.87	-5

74,459.53 308.49 ( 0.42%)

51,732.40 -631.16 (-1.21%)

7,581.68 -159.71 (-2.06%)

63,176.05 -1,483.42 (-2.29%)

10,722.51 0.44 (0.00%)

95.22 0.06 (0.06%)

106.19 0.24 (0.23%)

127.01 0.44 (0.35%)

0.60 0.00 (0.12%)